Nisa Investment Advisors LLC lifted its stake in PerkinElmer, Inc. (NYSE:PKI) by 0.5% during the 2nd quarter, Holdings Channel reports. The firm owned 87,515 shares of the medical research company’s stock after acquiring an additional 400 shares during the period. Nisa Investment Advisors LLC’s holdings in PerkinElmer were worth $8,584,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of PKI. Amundi Pioneer Asset Management Inc. boosted its position in shares of PerkinElmer by 1.3% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 128,822 shares of the medical research company’s stock worth $12,413,000 after purchasing an additional 1,695 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of PerkinElmer by 30.0% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,183 shares of the medical research company’s stock worth $505,000 after purchasing an additional 1,196 shares during the last quarter. AXA boosted its position in shares of PerkinElmer by 22.2% in the 4th quarter. AXA now owns 8,262 shares of the medical research company’s stock worth $803,000 after purchasing an additional 1,500 shares during the last quarter. Profund Advisors LLC bought a new position in shares of PerkinElmer in the 4th quarter worth $211,000. Finally, Geode Capital Management LLC boosted its position in shares of PerkinElmer by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 1,758,880 shares of the medical research company’s stock worth $170,448,000 after purchasing an additional 69,452 shares during the last quarter. Institutional investors and hedge funds own 93.34% of the company’s stock.
In other PerkinElmer news, insider Daniel R. Tereau sold 5,452 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $95.22, for a total transaction of $519,139.44. Also, Director Peter Barrett sold 7,552 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $100.11, for a total value of $756,030.72. Following the sale, the director now directly owns 29,552 shares of the company’s stock, valued at approximately $2,958,450.72. The disclosure for this sale can be found here. Corporate insiders own 0.62% of the company’s stock.
A number of equities research analysts have recently commented on the company. Needham & Company LLC started coverage on PerkinElmer in a research report on Monday, July 13th. They set a “hold” rating on the stock. JPMorgan Chase & Co. increased their target price on PerkinElmer from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Stifel Nicolaus lowered their target price on PerkinElmer from $102.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Cfra lowered their target price on PerkinElmer from $100.00 to $94.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Finally, Zacks Investment Research raised PerkinElmer from a “sell” rating to a “hold” rating and set a $105.00 target price for the company in a research note on Thursday, May 28th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $87.47.
NYSE PKI opened at $112.99 on Wednesday. The company has a market cap of $12.81 billion, a PE ratio of 28.18, a PEG ratio of 1.83 and a beta of 1.37. The company has a current ratio of 1.84, a quick ratio of 1.30 and a debt-to-equity ratio of 0.79. PerkinElmer, Inc. has a 12 month low of $62.91 and a 12 month high of $115.81. The stock has a 50 day moving average of $101.90 and a 200-day moving average of $92.05.
PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.70 by $0.87. The company had revenue of $811.91 million during the quarter, compared to the consensus estimate of $703.32 million. PerkinElmer had a return on equity of 16.52% and a net margin of 7.82%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.00 EPS. As a group, sell-side analysts predict that PerkinElmer, Inc. will post 4.01 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 16th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. The ex-dividend date is Thursday, October 15th. PerkinElmer’s payout ratio is presently 6.83%.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Read More: What can cause a stock to outperform?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.